Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Survival Benefit Plus Safety Profile Cements T-DM1 As Successor To Herceptin

This article was originally published in The Pink Sheet Daily

Executive Summary

Full results from the EMILIA study show that Roche’s antibody drug conjugate T-DM1 offers a 5.8 month survival benefit in mostly second-line advanced breast cancer. Reporting results in the New England Journal of Medicine, researchers highlight the effects regardless of line of therapy and the value of antibody drug conjugates in improving safety.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts